Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Xiaojing Du, Biwei Yang, Quanlin An, et al.
The Innovation (2021) Vol. 2, Iss. 2, pp. 100103-100103
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism
Mohammed A. S. Abourehab, Alaa M. Alqahtani, Bahaa G. M. Youssif, et al.
Molecules (2021) Vol. 26, Iss. 21, pp. 6677-6677
Open Access | Times Cited: 125
Long non-coding RNA mediated drug resistance in breast cancer
Deepshikha Singh, Yehuda G. Assaraf, Rajesh N. Gacche
Drug Resistance Updates (2022) Vol. 63, pp. 100851-100851
Closed Access | Times Cited: 83
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
Melissa L. Johnson, Marina Chiara Garassino, Tony Mok, et al.
Lung Cancer (2022) Vol. 170, pp. 41-51
Open Access | Times Cited: 79
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 36
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Ali Doostmohammadi, Hossein Jooya, Kimia Ghorbanian, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 27
Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application
Qianwen Guan, Shuaishuai Xing, Lei Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7788-7824
Closed Access | Times Cited: 26
HER2-targeted therapies in cancer: a systematic review
Kunrui Zhu, Xinyi Yang, Hebei Tai, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 24
Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy
Deepak Chandra Joshi, Anurag Sharma, Sonima Prasad, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 18
Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling
Kinjal Shah, Julhash U. Kazi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 51
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Drug Resistance Updates (2022) Vol. 66, pp. 100904-100904
Closed Access | Times Cited: 48
Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer
Anup Biswas, Seo-Young Han, Yifan Tai, et al.
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 1002-1021
Open Access | Times Cited: 43
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
Yufeng Li, Tianyu Mao, Jing Wang, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 36
Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, et al.
RSC Advances (2023) Vol. 13, Iss. 27, pp. 18825-18853
Open Access | Times Cited: 21
Targeting HER3 to overcome EGFR TKI resistance in NSCLC
Qiuqiang Chen, Gang Jia, Xilin Zhang, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 8
Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC
Emiliano Laudadio, Luca Mangano, Cristina Minnelli
ACS Chemical Biology (2024) Vol. 19, Iss. 4, pp. 839-854
Closed Access | Times Cited: 8
Genetic-informed alternative RNA splicing serves an essential role in carcinogenesis and prognosis of non-small-cell lung cancer
Hanyi Zhou, Ming Wu, Kui Wu, et al.
The Innovation Medicine (2025), pp. 100111-100111
Closed Access
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance
Sihong Chen, Yingxi Zhao, Shougeng Liu, et al.
Drug Resistance Updates (2022) Vol. 61, pp. 100821-100821
Closed Access | Times Cited: 32
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Valentina Favorito, Ilaria Ricciotti, Andrea De Giglio, et al.
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 2, pp. 139-154
Closed Access | Times Cited: 5
Anticancer potential of novel symmetrical and asymmetrical dihydropyridines against breast cancer via EGFR inhibition: molecular design, synthesis, analysis and screening
Syed Faizan, Sirajunisa Talath, Adil Farooq Wali, et al.
RSC Advances (2024) Vol. 14, Iss. 16, pp. 11368-11387
Open Access | Times Cited: 5
Macrocyclization strategy for improving candidate profiles in medicinal chemistry
Om Darlami, R.Y.K. Pun, Sung‐Hoon Ahn, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116501-116501
Closed Access | Times Cited: 5
Single molecule tracking based drug screening
D. Watanabe, Michio Hiroshima, Masato Yasui, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy(2006-present)
Yufeng An, Xinya Lv, Shidi Xu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117268-117268
Closed Access
Gene Editing in ErbB/HER Family-Mediated Cancer Immunology
Ling Yin
IntechOpen eBooks (2025)
Closed Access
In Vitro Functional Validation of an Anti-FREM2 Nanobody for Glioblastoma Cell Targeting
Gloria Krapež, Neja Šamec, Alja Zottel, et al.
Antibodies (2025) Vol. 14, Iss. 1, pp. 8-8
Open Access
Deciphering the Effect of Phytocompounds In Vitro and Mechanism Using Bioinformatic Tools in Glioblastoma
Megha Gautam, Reema Gabrani
Proceedings of the National Academy of Sciences India Section B Biological Sciences (2025)
Closed Access
Page 1 - Next Page

Scroll to top